MX2010000502A - Compuestos y metodos para modular fxr. - Google Patents

Compuestos y metodos para modular fxr.

Info

Publication number
MX2010000502A
MX2010000502A MX2010000502A MX2010000502A MX2010000502A MX 2010000502 A MX2010000502 A MX 2010000502A MX 2010000502 A MX2010000502 A MX 2010000502A MX 2010000502 A MX2010000502 A MX 2010000502A MX 2010000502 A MX2010000502 A MX 2010000502A
Authority
MX
Mexico
Prior art keywords
compounds
methods
modulating fxr
fxr
modulating
Prior art date
Application number
MX2010000502A
Other languages
English (en)
Inventor
Alan M Warshawsky
Michael James Genin
Ana Belen Bueno Melendo
Peter Rudolph Mannien
Francisco Javier Agejas-Chicharro
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2010000502A publication Critical patent/MX2010000502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

Se describen compuestos de la fórmula (I), en donde las variables son como se define en la presente y sus composiciones farmacéuticas y métodos de uso son útiles para tratar dislipidemia y enfermedades relacionadas con dislipidemia.
MX2010000502A 2007-07-16 2008-07-11 Compuestos y metodos para modular fxr. MX2010000502A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16
PCT/US2008/069719 WO2009012125A1 (en) 2007-07-16 2008-07-11 Compounds and methods for modulating fxr

Publications (1)

Publication Number Publication Date
MX2010000502A true MX2010000502A (es) 2010-03-26

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000502A MX2010000502A (es) 2007-07-16 2008-07-11 Compuestos y metodos para modular fxr.

Country Status (31)

Country Link
US (1) US8153624B2 (es)
EP (1) EP2178851B1 (es)
JP (1) JP5373788B2 (es)
KR (1) KR101157334B1 (es)
CN (1) CN101743232B (es)
AR (1) AR067540A1 (es)
AT (1) ATE539065T1 (es)
AU (1) AU2008276236B2 (es)
BR (1) BRPI0814571A2 (es)
CA (1) CA2693406C (es)
CL (1) CL2008002051A1 (es)
CO (1) CO6270212A2 (es)
CY (1) CY1112298T1 (es)
DK (1) DK2178851T3 (es)
DO (1) DOP2010000018A (es)
EA (1) EA016475B1 (es)
EC (1) ECSP109879A (es)
ES (1) ES2376176T3 (es)
HR (1) HRP20120048T1 (es)
IL (1) IL202234A0 (es)
MA (1) MA31683B1 (es)
MX (1) MX2010000502A (es)
PE (1) PE20090809A1 (es)
PL (1) PL2178851T3 (es)
PT (1) PT2178851E (es)
RS (1) RS52216B (es)
SI (1) SI2178851T1 (es)
SV (1) SV2010003458A (es)
TN (1) TN2010000028A1 (es)
TW (1) TW200906823A (es)
WO (1) WO2009012125A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2014500318A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
WO2012087521A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
AU2014320463B2 (en) 2013-09-11 2018-08-02 Centre National De La Recherche Scientifique (Cnrs) Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
MA40814A1 (fr) 2015-02-06 2019-08-30 Intercept Pharmaceuticals Inc Compositions pharmaceutiques pour thérapie combinée
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN107427527B (zh) 2015-03-31 2021-01-26 英安塔制药有限公司 作为fxr/tgr5激动剂的胆汁酸衍生物及其使用方法
KR20170132879A (ko) 2015-04-07 2017-12-04 인터셉트 파마슈티컬즈, 인크. 조합 요법을 위한 약제학적 조성물
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
KR20180124123A (ko) 2016-03-28 2018-11-20 인터셉트 파마슈티컬즈, 인크. Fxr 효능제 및 arb의 조합에 의해 얻어지는 의약
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) * 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN116854681A (zh) * 2016-08-23 2023-10-10 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
CN109689050A (zh) * 2016-09-14 2019-04-26 诺华股份有限公司 Fxr激动剂的新方案
BR112019006651A2 (pt) 2016-10-04 2019-07-02 Enanta Pharm Inc análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
NZ758117A (en) * 2017-04-12 2022-01-28 Il Dong Pharma Isoxazole derivatives as nuclear receptor agonists and uses thereof
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
WO2019055808A1 (en) 2017-09-14 2019-03-21 Ardelyx, Inc. HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS
BR112020008121A2 (pt) 2017-11-01 2020-11-03 Bristol-Myers Squibb Company compostos espirocíclico de alqueno como moduladores de receptor farnesoide x
EA202091101A1 (ru) 2017-11-01 2020-08-06 Бристол-Маерс Сквибб Компани Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора
SG11202003827YA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
EP3704107B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
ES2944657T3 (es) * 2017-11-01 2023-06-23 Bristol Myers Squibb Co Compuestos de alqueno como moduladores del receptor farnesoide X
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US11667629B2 (en) 2017-12-22 2023-06-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Isoxazole derivative, preparation method therefor, and use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
JP2022508402A (ja) * 2018-08-30 2022-01-19 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の治療
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
CN113439078B (zh) 2019-02-19 2024-04-23 吉利德科学公司 Fxr激动剂的固体形式
WO2020231917A1 (en) * 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
JP2022536060A (ja) 2019-05-30 2022-08-12 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物
MX2022000742A (es) 2019-07-18 2022-02-14 Enyo Pharma Metodo para disminuir los efectos adversos del interferon.
CA3160445A1 (en) * 2019-11-08 2021-05-14 Terns Pharmaceuticals, Inc. Treating liver disorders
EP4090327A1 (en) 2020-01-15 2022-11-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of fxr agonists for treating an infection by hepatitis d virus
AU2021273487A1 (en) * 2020-05-13 2023-01-05 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
MX2023002308A (es) 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.
JP2023541423A (ja) * 2020-09-11 2023-10-02 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｆｘｒアゴニストの固体分散体製剤
IL302099A (en) * 2020-10-15 2023-06-01 Lilly Co Eli FXR agonist polymorphs
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
AU2022387121A1 (en) 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
EP1140079B1 (en) 1998-12-23 2009-06-03 Glaxo Group Limited Assays for ligands for nuclear receptors
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2003248861B2 (en) 2002-07-09 2009-01-22 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2004048349A1 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
BRPI0707427A2 (pt) * 2006-02-03 2011-05-03 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar dislipidemia, aterosclerose, e diabetes e complicações da mesma, para elevar os nìveis plásmicos de hdl, e para diminuir triglicerìdeos plásmicos, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
TW200812982A (en) 2006-05-24 2008-03-16 Lilly Co Eli Compounds and methods for modulating FXR
WO2007140183A1 (en) 2006-05-24 2007-12-06 Eli Lilly And Company Fxr agonists

Also Published As

Publication number Publication date
CL2008002051A1 (es) 2009-05-29
ATE539065T1 (de) 2012-01-15
PE20090809A1 (es) 2009-06-27
TN2010000028A1 (en) 2011-09-26
EP2178851B1 (en) 2011-12-28
CN101743232A (zh) 2010-06-16
PT2178851E (pt) 2012-02-27
US20100152166A1 (en) 2010-06-17
HRP20120048T1 (hr) 2012-02-29
DK2178851T3 (da) 2012-02-06
AU2008276236A1 (en) 2009-01-22
ES2376176T3 (es) 2012-03-09
EP2178851A1 (en) 2010-04-28
CN101743232B (zh) 2013-03-06
JP2010533722A (ja) 2010-10-28
SV2010003458A (es) 2011-01-10
IL202234A0 (en) 2010-06-16
JP5373788B2 (ja) 2013-12-18
US8153624B2 (en) 2012-04-10
CA2693406C (en) 2014-04-29
CO6270212A2 (es) 2011-04-20
AR067540A1 (es) 2009-10-14
RS52216B (en) 2012-10-31
WO2009012125A1 (en) 2009-01-22
AU2008276236B2 (en) 2013-03-14
EA201070148A1 (ru) 2010-06-30
ECSP109879A (es) 2010-02-26
CA2693406A1 (en) 2009-01-22
PL2178851T3 (pl) 2012-05-31
KR101157334B1 (ko) 2012-06-15
EA016475B1 (ru) 2012-05-30
BRPI0814571A2 (pt) 2015-01-06
DOP2010000018A (es) 2010-01-31
MA31683B1 (fr) 2010-09-01
SI2178851T1 (sl) 2012-02-29
CY1112298T1 (el) 2015-12-09
TW200906823A (en) 2009-02-16
KR20100020999A (ko) 2010-02-23

Similar Documents

Publication Publication Date Title
TN2010000028A1 (en) Compounds and methods for modulating fxr
PL2029547T3 (pl) Agoniści FXR
WO2007140174A3 (en) Compounds and methods for modulating fxr
WO2007092751A3 (en) Compounds and methods for modulating fx-receptors
MX2011009796A (es) Inhibidores de la cinasa pi3.
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
MX2010006421A (es) Compuestos organicos.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
EA201100447A1 (ru) Органические соединения
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MY162022A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
EP2571876A4 (en) SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
MY153057A (en) Tryclic compounds,compositions and methods
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
HK1131971A1 (en) Benzimidazole modulators of vr1 vr1
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IN2015DN01151A (es)

Legal Events

Date Code Title Description
FG Grant or registration